ALS Limited Accelerates Digital Labs Amid Record FY26 Growth and Leadership Refresh

Record FY26 Performance Anchored by Minerals Surge

ALS Limited (ASX:ALQ) closed FY26 on a high note, delivering a record year characterised by a 20.2% organic growth in its Minerals segment. This surge was fuelled by robust sample volume increases and a favourable pricing environment in the second half, reinforcing ALS’s dominant position in resource exploration testing. Margins expanded significantly, benefiting from operating leverage and improved market conditions.

Industrial Materials also posted solid organic revenue growth, although margin performance was mixed across its sub-sectors. Oil & Lubricants achieved a strong 12.2% organic growth despite some margin compression, while Coal grew 7.6% but faced margin pressure from higher occupancy costs.

Life Sciences Faces Mixed Outcomes but Growth in Environmental

The Life Sciences division, comprising Environmental, Food, and Pharma businesses, presented a more nuanced picture. The Environmental business, ALS’s largest revenue contributor at 35%, delivered mid-single-digit organic growth in key APAC and EMEA markets, driven by increasing PFAS regulation and environmental remediation demand. However, softer conditions in the Americas, particularly around York’s integration and regulatory challenges, weighed on performance.

Food testing sustained its momentum with a third consecutive year of 7.2% organic growth, led by strong European demand. Pharma experienced a slight 1.6% decline in organic revenue, but the standout was Nuvisan, which saw EBIT soar 123% and margin improvement of approximately 450 basis points following a successful transformation program.

Strategic Refresh: Roadmap to Win and Leadership Renewal

ALS’s refreshed strategic blueprint, dubbed the Roadmap to Win, sharpened the company’s focus on high-volume analytical testing markets where it can build sustainable competitive advantages. The strategy is underpinned by seven key enablers including culture, capital discipline, operational excellence, sustainability, customer relationships, innovation, and sector expertise.

Leadership transitions marked FY26, with long-serving executives Bruce McDonald and Tim Kilmister retiring after 22 and 31 years respectively. New appointments include Andrea Vallejo as Executive General Manager Environmental, based in Madrid, and Rajkumar Mathiravedu as Global Executive General Manager Minerals, bringing extensive industry experience. Meanwhile, Group Treasurer Michael Williams announced his departure after 23 years, signaling a significant shift in the company’s senior team.

Digital Transformation Accelerates with Lab of the Future

ALS is pushing forward with its Lab of the Future initiative, integrating data analytics, robotics, and artificial intelligence to enhance laboratory productivity and quality. The company’s unified Laboratory Information Management System (LIMS) now supports 80% of group revenue, creating a proprietary data moat developed over 30 years and across 450 labs.

Earlier in 2026, ALS launched an internal AI Marketplace providing secure GenAI tools to over 5,000 employees at minimal cost. This digital infrastructure aims to reduce routine tasks, enabling staff to focus on higher-value expertise, with early returns already evident. The company anticipates these investments will scale, driving margin improvement and client outcomes over time.

Q1 FY27 Trading and Capital Allocation Update

ALS confirmed it remains on track to meet its FY27 guidance of high single-digit organic revenue growth and margin expansion. The Commodities segment, particularly Minerals, is running ahead of expectations, buoyed by sustained exploration activity and growing junior miner participation. Margins are expected to benefit from favourable pricing and operating leverage as the year progresses.

Life Sciences showed a slow start but improved through the quarter, with Food achieving mid-single-digit growth, Environmental low-single-digit growth, and Pharma experiencing a slight decline. The Nuvisan pipeline remains promising despite some expected margin compression compared to the previous year’s first half.

On the capital front, ALS is progressing hub lab upgrades on schedule and budget, with commissioning expected in Sydney and Peru within the year. The company also signed an agreement to increase its stake in the Saudi joint venture to 60%, pending regulatory approvals, reflecting its disciplined approach to portfolio optimisation and growth.